Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 28, 2015; 21(16): 5032-5038
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.5032
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.5032
Table 1 Demographic and clinical data at baseline (intention-to-treat population) n (%)
MOX-ST | CLA-ST | P value | |
Included in ITT analysis | 80 | 81 | NS |
Age (yr), mean ± SD | 59.3 ± 13.1 | 59.4 ± 13.1 | 0.235 |
Gender (male) | 34 (42.5) | 33 (40.7) | 0.773 |
BMI (kg/m2), mean ± SD | 22.9 ± 2.2 | 22.7 ± 2.9 | 0.352 |
Current smoker | 11 (13.7) | 10 (12.3) | 0.385 |
Alcohol drinking | 13 (16.2) | 9 (11.1) | 0.351 |
Diabetes | 5 (6.2) | 8 (9.8) | 0.125 |
Hypertension | 19 (23.7) | 23 (28.3) | 0.407 |
Previous history of peptic ulcer | 12 (15.0) | 9 (11.1) | 0.348 |
Endoscopic diagnosis | 0.624 | ||
Gastritis | 70 (87.6) | 70 (86.6) | |
Gastric ulcer | 4 (5.0) | 5 (6.1) | |
Duodenal ulcer | 1 (1.2) | 1 (1.2) | |
Gastric and duodenal ulcer | 1 (1.2) | 0 (0.0) | |
Adenoma | 4 (5.0) | 4 (4.9) | |
Dysplasia | 0 (0.0) | 1 (1.2) | |
Positive CLOtest | 59 (73.7) | 62 (76.5) | 0.955 |
H. pylori colonization | 0.588 | ||
Negative | 3 (3.7) | 5 (6.1) | |
Mild | 34 (42.5) | 36 (44.4) | |
Moderate | 32 (40.0) | 24 (29.6) | |
Marked | 11 (13.8) | 16 (19.9) | |
Atrophic change | 8 (10.0) | 2 (2.4) | 0.087 |
Intestinal metaplasia | 10 (12.5) | 13 (16.0) | 0.761 |
Drop out | 2 (2.5) | 4 (4.9) | 0.113 |
Noncompliance | 0 (0.0) | 0 (0.0) | |
Follow-up loss | 2 (2.5) | 4 (4.9) | |
Discontinued therapy due to adverse events | 0 (0.0) | 0 (0.0) |
Table 2 Helicobacter pylori eradication rates
MOX-ST | CLA-ST | P value | |
ITT analysis | |||
Eradication rate | 91.3% (73/80) | 71.6% (58/81) | 0.014 |
95%CI | 86.2%-95.4% | 65.8%-77.4% | |
PP analysis | |||
Eradication rate | 93.6% (73/78) | 75.3% (58/77) | 0.022 |
95%CI | 89.1%-98.1% | 69.4%-81.8% |
Table 3 Univariate analysis of clinical factors influencing the efficacy
MOX-ST | CLA-ST | |||
Eradication rate | P value | Eradication rate | P value | |
Age (yr) | 0.436 | 0.002 | ||
< 60 | 97.2% (35/36) | 81.1% (30/37) | ||
≥ 60 | 90.4% (38/42) | 70.0% (28/40) | ||
Gender | 0.383 | 0.622 | ||
Male | 91.1% (31/34) | 71.8% (23/32) | ||
Female | 95.4% (42/44) | 77.7% (35/45) | ||
Body mass index | 0.651 | 0.743 | ||
< 25 | 95.2% (20/21) | 86.9% (20/23) | ||
≥ 25 | 92.9% (53/57) | 70.3% (38/54) | ||
Smoking | 0.585 | 0.377 | ||
(-) | 97.0% (65/67) | 77.6% (52/67) | ||
(+) | 72.7% (8/11) | 60.0% (6/10) | ||
Alcohol | 0.417 | 0.082 | ||
(-) | 96.9% (63/65) | 77.9% (53/68) | ||
(+) | 76.9% (10/13) | 55.5% (5/9) | ||
Diabetes | 0.706 | 0.107 | ||
(-) | 94.5% (70/74) | 76.8% (53/69) | ||
(+) | 75.0% (3/4) | 62.5% (5/8) | ||
Hypertension | 0.322 | 0.096 | ||
(-) | 91.6% (55/60) | 79.6% (43/54) | ||
(+) | 100.0% (18/18) | 65.2% (15/23) | ||
History of ulcer | 0.454 | 0.828 | ||
(-) | 92.5% (62/67) | 75.0% (51/68) | ||
(+) | 100.0% (11/11) | 77.7% (7/9) | ||
Presence of ulcer | 0.352 | 0.076 | ||
(-) | 92.6% (63/68) | 78.7% (52/66) | ||
(+) | 100.0% (10/10) | 54.5% (6/11) | ||
Positive CLOtest | 0.259 | 0.374 | ||
(-) | 76.1% (16/21) | 63.1% (12/19) | ||
(+) | 100.0% (57/57) | 79.3% (46/58) | ||
Atrophic change | 0.111 | 0.071 | ||
(-) | 95.7% (67/70) | 76.0% (57/75) | ||
(+) | 75.0% (6/8) | 50.0% (1/2) | ||
Intestinal metaplasia | 0.270 | 0.322 | ||
(-) | 95.5% (65/68) | 76.5% (49/64) | ||
(+) | 80.0% (8/10) | 69.2% (9/13) | ||
Bacterial density | 0.296 | 0.507 | ||
None | 66.7% (2/3) | 60.0% (3/5) | ||
Mild | 90.6% (29/32) | 67.6% (23/34) | ||
Moderate | 100.0% (32/32) | 78.2% (18/23) | ||
Marked | 90.9% (10/11) | 93.3% (14/15) | ||
Compliance | NS | NS | ||
Poor | 0.0% (0/0) | 0.0% (0/0) | ||
Good | 93.6% (73/78) | 75.3% (58/77) | ||
Adverse events | 0.493 | 0.494 | ||
(-) | 92.6% (63/68) | 77.6% (45/58) | ||
(+) | 100.0% (10/10) | 68.4% (13/19) |
Table 4 Adverse events and compliance n (%)
Adverse events | MOX-ST(n = 78) | CLA-ST(n = 77) | P value |
Bloating/dyspepsia | 4 (5.1) | 4 (5.3) | 0.383 |
Taste distortion | 3 (3.8) | 5 (6.4) | 0.316 |
Epigastric discomfort | 2 (2.6) | 5 (6.4) | 0.296 |
Nausea | 1 (1.3) | 1 (1.3) | 0.505 |
Abdominal pain | 0 (0.0) | 1 (1.3) | 0.309 |
Diarrhea | 0 (0.0) | 3 (3.9) | 0.075 |
Constipation | 0 (0.0) | 0 (0.0) | NS |
Total | 10 (12.8) | 19 (24.6) | 0.038 |
Compliance, n (%) | 78 (100.0) | 77 (100.0) | NS |
-
Citation: Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of
Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015; 21(16): 5032-5038 - URL: https://www.wjgnet.com/1007-9327/full/v21/i16/5032.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i16.5032